Drug intelligence / Profile preview

psilocybin (b2f2f8)

Development stage: Unknown
Lead developer: University of Southern California
Modality: Small Molecules
Administration: Oral

Overview

Psilocybin is a naturally occurring psychedelic tryptamine alkaloid and phosphorylated prodrug of psilocin. Following dephosphorylation to psilocin, it produces psychedelic effects primarily through partial agonism of the serotonin 2A receptor. The University of Southern California is evaluating a single supervised psilocybin dose, with or without an eight-week mindfulness-training program, in a Phase 2 pilot study in healthy adults to assess feasibility and effects on stress and mental-health measures. ([pubchem.ncbi.nlm.nih.gov](https://pubchem.ncbi.nlm.nih.gov/compound/Psilocybin))

Other names: IndocybinPsilocibinPsilocybine

Targets

HTR2A (Serotonin receptor 5-HT2A)

Beyond the preview

Go deeper on psilocybin (b2f2f8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on psilocybin (b2f2f8).

Explore the full profile